RB1 and cancer: Firstly, although we show that the increase of ROS by the combination of CDK4/6i and PARPi is the dominant mechanism to synergistically inhibit RB-deficient cancer cells, we cannot exclude other mechanisms that may also cooperate or contribute to this synergistic effect.